On a Tuesday in early 2024, I got an email I almost archived. A procurement director at a hospital system I had worked with for years forwarded a vendor comparison table. Her analyst had pulled the list price for a standard cervical plate-and-screw construct from three potential suppliers. The subject line was blunt: “Are we overpaying for NuVasive?”
That question used to annoy me. After four years as a quality and compliance manager in spinal med-tech, I’ve learned to see it differently. My job is to review everything clinical before it reaches a customer—technique guides, training slides, support documentation. Upwards of 200 items a year. In the first half of 2024, I rejected around a dozen first drafts—maybe 12%, I’d have to check the report but it’s close—because the claims couldn’t be backed by data or the support path wasn’t obvious. That rejection habit is why the email bothered me.
Attached to her email was the NuVasive ACDF surgical technique PDF. It’s the 24-page guide our education team maintains for anterior cervical discectomy and fusion—a detailed walk-through of patient positioning, exposure, discectomy, trialing, and implant insertion. It wasn’t the whole document, though. She had screenshotted page 18: the implant options. “Help me understand why this plate should cost more than a comparable one.”
From the Outside, a Merger Looks Like a Catalog Change
To answer her honestly, I had to talk about something bigger. The Globus Medical NuVasive acquisition was still fresh—announced in April 2023 and completed in September of that year. On paper, it meant NuVasive’s minimally invasive spine portfolio and clinical education model now sat inside Globus Medical, which brought its own robotics and enabling technology. For procurement teams, it looked like a price list getting longer.
What looked like a catalog change was actually a support-structure change. NuVasive had spent years building something that doesn’t show up on an implant invoice: a clinical services team, surgical technique education, and step-by-step guides like the ACDF PDF that surgeons have been downloading since before I joined this industry. When you combine that with Globus’s product line, you’re not just buying a plate from a bigger vendor.
But you can’t put “clinical education infrastructure” on a purchase order. So people don’t count it.
The Question Behind the Price Question
I started an internal review, more out of stubbornness than strategy. We looked at every ACDF education asset we had produced in the previous 18 months. Surgeons were downloading the NuVasive ACDF surgical technique PDF more often than almost any other resource. Yet when I sat in on interviews with surgeons and OR managers, almost nobody mentioned the implant cost as the reason they chose our system. They talked about knowing the approach, about having somebody answer the phone.
The turning point was a meeting at a regional hospital that was starting its first ACDF program. They had already signed a supply agreement with a competing implant company at a lower price. The OR manager was gracious about the wasted afternoon, but direct. She said, “Look, I can buy a comparable plate for less. What I can’t buy from them is the band around it—someone to train my nurses, a dry lab for my surgeons, and advice when the case looks different from the PDF.”
I remember almost smiling, because she had put her finger on the exact surface illusion in our industry. From the outside, every spine company sells the same kit: implant, instruments, technique guide. From the inside, the difference is what surrounds the kit. The guide itself isn’t the product. It’s the tip of the iceberg.
You’re not buying the plate. You’re buying the confidence of the person placing it—and the support team that gives them that confidence.
People assume the cheapest quote is the most efficient purchasing decision. What they don’t see is which costs are hidden or deferred. A $150 savings on an implant disappears if the surgical team misses half the steps of the new system’s workflow. Add the cost of a delayed case, extra OR time, or an avoidable readmission, and the cheaper number stops looking cheap.
The not-so-obvious part is that patient complexity doesn’t stop at the implant. A patient considering ACDF at 82 years old might already use a power wheelchair because cervical myelopathy has affected their walking. In the OR, someone will be monitoring their oxygen saturation on a pulse oximeter from the moment they’re sedated. If that patient also has type 2 diabetes, an anesthesia provider may ask, “How does a CGM work?” before deciding how tightly to manage glucose through an outpatient fusion. A continuous glucose monitor—a CGM—uses a small sensor under the skin to measure interstitial glucose at regular intervals. None of that context arrives in an implant quote.
That’s why, after the audit, we changed our ACDF educational material again, but not by adding more pages. We asked our clinical specialists to write a short implementation guide that named the resources: initial case observation, instrument verification list, training videos, and the support contact for new staff. We published it beside the NuVasive ACDF surgical technique PDF. It felt obvious. It also felt late.
The response to the original email was simpler than I expected. I didn’t send a price defense. I replied with three attachments: the latest NuVasive ACDF surgical technique PDF, the implementation guide we had just approved, and the name of the clinical specialist who would handle their first cases. My note said: “Let’s talk about what the price includes, not what the implants weigh.”
She didn’t reply for a week. Then came the message I’ve used as my own checklist since: “I still wish your plate was cheaper. But I can’t show my surgeons a comparison table when the real difference is in a PDF and a support phone number. We’re staying.”
I’m not telling this story because we won a contract. I’m telling it because we almost lost it for the wrong reason.
What I Learned From the Review
First, mergers don’t create value by themselves. The value is in how a sales force, a clinical support team, and an education group actually talk to each other. After the Globus Medical NuVasive acquisition, surgeons and buyers asked us the same question: “What changed for me?” The most useful answer isn’t a chart of products. It’s an honest description of training capacity and technique resources.
Second, quality claims need the same verification as implant specifications. When my team writes “clinical support available,” I make them define it. How quickly? Who responds? What happens at 6:00 a.m. for an early case? When I started enforcing that rule, the first drafts got messier—but the final work got better.
Third, total value is not the same as a premium price. The real calculation includes what it costs to switch systems, to retrain staff, to lose OR time while a team learns a new workflow. A quote is only one line in that equation.
I’m not saying ignore price. Price is part of every decision. I’m saying that in spine surgery, the least expensive option often becomes the most expensive after you add training time, uncertainty, and the risk of a surgeon defaulting back to the old system. That’s not a marketing point. It’s a total-cost point.
If you’re evaluating a new spine partner, start with the technique guide—ask for the NuVasive ACDF surgical technique PDF or whatever equivalent fits your case. Then ask for their implementation plan. Make them show you how a brand-new OR team gets to competent. That’s where real quality lives. And it rarely shows up on a spreadsheet.
